Giotrif
(Afatinib)
(40 mg)
(28)
(Tablets)
Giotrif (afatinib) 40 mg 28 tabs BERINGER Germany
Article:
Indications
As monotherapy in patients who have not previously received tyrosine kinase inhibitors for the treatment of locally advanced or metastatic non-small cell lung cancer with a mutation (mutations) of the EGFR epidermal growth factor receptor.
1650ct
-
Commercial name:Giotrif
-
Сhemical name:Afatinib
-
Dosage:40 mg
-
Quantity:28
-
Release form:Tablets
No reviews yet